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ABSTRACT  24 
Canine influenza viruses (CIVs) cause a contagious respiratory disease in 25 
dogs. CIV subtypes include H3N8, which originated from the transfer of H3N8 26 
equine influenza virus (EIV) to dogs; and the H3N2, which is an avian-origin virus 27 
adapted to infect dogs. Only inactivated influenza vaccines (IIVs) are currently 28 
available against the different CIV subtypes. However, the efficacy of these CIV 29 
IIVs is not optimal and improved vaccines are necessary for the efficient 30 
prevention of disease caused by CIVs in dogs. Since live-attenuated influenza 31 
vaccines (LAIVs) induce better immunogenicity and protection efficacy than IIVs, 32 
we have combined our previously described H3N8 and H3N2 CIV LAIVs to 33 
create a bivalent vaccine against both CIV subtypes. Our findings show that, in a 34 
mouse model of infection, the bivalent CIV LAIV is safe and able to induce, upon 35 
a single intranasal immunization, better protection than that induced by a bivalent 36 
CIV IIV against subsequent challenge with H3N8 or H3N2 CIVs. These 37 
protection results also correlated with the ability of the bivalent CIV LAIV to 38 
induce better humoral immune responses. This is the first description of a 39 
bivalent LAIV for the control and prevention of H3N8 and H3N2 CIV infections in 40 
dogs.  41 
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INTRODUCTION  47 
Influenza A virus (IAV) is an important pathogen that can infect a number of 48 
different hosts, including fowl, humans, pigs, horses and dogs, causing 49 
respiratory disease, provoking an elevated number of deaths, and resulting in 50 
substantial economic impact [1]. Canine influenza is a contagious respiratory 51 
disease produced by two subtypes of canine influenza viruses (CIVs): H3N8 that 52 
was transmitted from horses to dogs around 1999 in the United States (US) [2], 53 
and the avian-origin H3N2 that was transferred to dogs around 2005 in China 54 
and which has been circulating in Asia since then [3, 4]. In 2015, the first 55 
outbreak of CIV H3N2 occurred in the US [5]. While H3N8 CIV infections were 56 
only reported in dogs [6, 7], CIV H3N2 has also been isolated from cats in South 57 
Korea and more recently in the US [8-10]. Both H3N8 and H3N2 CIVs are able to 58 
rapidly spread among dogs in some geographical regions of the USA [2, 10-13], 59 
representing an important hazard for the health of the canine population in the 60 
US and worldwide. Natural and experimental dog infections with human IAVs 61 
have been reported [14, 15] and reassortant viruses between the H3N2 CIV and 62 
the 2009 human pandemic H1N1 (pH1N1) viruses were isolated from infected 63 
dogs in Korea [16-18]. Two human IAV pandemics have initiated around 1918 64 
and 2009 when novel viruses are introduced in the human population, while 65 
others derived from the introduction of novel gene segments into the pre-existing 66 
human viruses [19, 20]. Because dogs live in close contact with humans, the 67 
emergence of new viruses in dogs that can infect humans represents a zoonotic 68 
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risk, which makes the control of CIV infections in the dog population important 69 
not only for canine health, but also likely for human wellbeing. 70 
Currently, only inactivated influenza vaccines (IIVs) are available for the 71 
prevention of CIV infections in dogs [10]. Historically, live attenuated influenza 72 
vaccines (LAIVs) have been shown to induce better immunogenicity and 73 
protection than IIVs [21, 22]. This is due by the fact that IIVs produce humoral 74 
immunity, mostly by the induction of neutralizing antibodies against the viral 75 
hemagglutinin (HA) protein, but limited induction of cellular immune responses, 76 
while LAIVs are able to induce both humoral and cellular immune responses [23-77 
25]. Human LAIVs contain three (trivalent) or four (quadrivalent) reassortant 78 
viruses that contain the six internal genes of a temperature-sensitive (ts), cold-79 
adapted (ca) and attenuated (att) master donor virus (MDV) along with the HA 80 
and neuraminidase (NA) viral segments from strains recommended by national 81 
and international public health agencies [26-29]. Previously we have described 82 
the generation, using reverse genetics techniques, of individual LAIVs for the 83 
prevention of either H3N8 [30] or H3N2 [31] CIVs. The H3N8 CIV LAIV [30] 84 
contained four mutations that were responsible for the ts, ca and att phenotype of 85 
the human MDV A/Ann Arbor/6/60 H2N2 LAIV [32, 33] in the PB2 (N265S) and 86 
PB1 (K391E, E581G, A661T) viral segments (D34N is natively present) of H3N8 87 
CIV. The H3N2 CIV LAIV was prepared as a recombinant virus containing the 88 
internal genes of the MDV H3N8 CIV LAIV [30] and the HA and NA viral 89 
segments of the newly introduced H3N2 CIV [31]. In a mouse model of infection, 90 
both LAIVs were safe and able to induce, upon a single intranasal immunization, 91 
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complete protection against homologous challenges with their respective 92 
parental form of the virus [30, 31]. Both the H3N8 and H3N2 LAIVs induced 93 
better immune B cell responses and detectable T cell responses than IIVs, 94 
suggesting that they would provide better vaccine protection for the control of the 95 
H3N8 or H3N2 CIV infections [30, 31]. However, each individual vaccine did not 96 
confer protection against challenge with the heterologous CIV [30, 31].  97 
Here, we report the development of a bivalent LAIV for the prevention of 98 
H3N8 and H3N2 CIVs based on our previously described individual LAIVs. Our 99 
results demonstrate that the bivalent CIV LAIV is safe and able to induce, upon a 100 
single intranasal administration, protective immunity against exposure to both 101 
H3N8 and H3N2 CIVs.  102 
 103 
MATERIALS AND METHODS 104 
Cells and viruses 105 
Madin-Darby canine kidney cells (MDCK; ATCC CCL-34) were grown in 106 
Dulbecco’s modified Eagle’s medium (DMEM; Mediatech, Inc.) supplemented 107 
with 10% fetal bovine serum (FBS), and 1% PSG (penicillin, 100 units/ml; 108 
streptomycin 100 µg/ml; L-glutamine, 2 mM) at 37ºC with 5% CO2 [30, 31]. 109 
Influenza A/Ca/IL/41915/2015 H3N2 wild-type (CIV H3N2 WT) was provided 110 
from the Baker Institute for Animal Health at Cornell University. Influenza 111 
A/Ca/NY/dog 23/2009 H3N8 wild-type (CIV H3N8 WT) [34, 35] and LAIV (CIV 112 
H3N8 LAIV) [30]; and CIV H3N2 LAIV [31] were described previously. Viruses 113 
were propagated in MDCK cells at 33ºC [30, 31, 36, 37]. Viral titers were 114 
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determined by immunofocus assay (fluorescent forming units, FFU/ml) in MDCK 115 
cells at 33ºC [30, 31, 37] using monoclonal antibodies (mAbs) against the viral 116 
NP: HB-65 (ATCC, H16-L10-4R5) for CIV H3N8 (WT and LAIV) and CIV H3N2 117 
LAIV; and HT-103 [38] for CIV H3N2 WT. 118 
Indirect immunofluorescence 119 
MDCK cells (48-well plate format, 1x105 cells/well, triplicates) were infected 120 
with the indicated viruses at a multiplicity of infection (MOI) of 3 [30, 31]. Infected 121 
cells were incubated for 12 h at 33°C and then fixed and permeabilized (4% 122 
formaldehyde, 0.5% Triton X-100 in PBS) for 15 min at RT. Cells were 123 
subsequently incubated in blocking solution (2.5% bovine albumin, BA, in PBS) 124 
for 1 h at RT. CIV-infected cells were incubated with 2 µg/ml of mAbs 125 
A/equine/Miami/1/63 H3N8 (anti-HA) or HB-65 (anti-NP); with a 1:1,000 dilution 126 
of goat polyclonal sera (pAb) anti-NA A/Singapore/1/57 H3N2 (BEI Resources 127 
NR-3137); and with a mixture of mAb Equine 7.1 and pAb anti-NA 128 
A/Singapore/1/57 H3N2 (2 µg/ml and 1:1,000 dilution, respectively) diluted in 129 
blocking solution for 1 h at 37ºC. After washing with PBS, cells were incubated 130 
with a 1:200 dilution of a Alexa-Fluor 594-conjugated secondary anti-mouse 131 
antibody, a fluorescein isothiocyanate (FITC)-conjugated secondary anti-goat 132 
antibody or with a mixture of both secondary antibodies in blocking solution; 133 
together with 4’,6-diamidino-2-phenylindole (DAPI; Research Organics) for 1 h at 134 
37°C. After washing with PBS, cells were examined and photographed using a 135 
fluorescent microscope (Olympus IX81) and camera (QIMAGING, Retiga 2000R).  136 
Mouse Infections 137 
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Six- to eight-week-old female C57BL/6 mice were purchased from the 138 
National Cancer Institute (NCI) and maintained in the animal care facility at the 139 
University of Rochester under specific pathogen-free conditions. All animal 140 
protocols were approved by the University Committee of Animal Resources and 141 
complied with the recommendations in the Guide for the Care and Use of 142 
Laboratory Animals of the National Research Council [39]. To evaluate the 143 
attenuation of the bivalent LAIV in vivo, mice (N = 12) were anesthetized 144 
intraperitoneally (i.p.) with 2,2,2-tribromoethanol (Avertin; 240 mg/kg of body 145 
weight) and then inoculated intranasally (i.n.) with 30 µl of a virus preparation 146 
containing 103 FFU of CIV H3N2 LAIV and 104 (N = 6) or 105 (N = 6) FFU of CIV 147 
H3N8 LAIV. Consistent with previous studies, no signs of infection were 148 
observed after mouse inoculation with CIV H3N2 or CIV H3N8 WT or LAIV [30, 149 
31, 35],. For this reason virus replication was determined by measuring viral titers 150 
in the lungs and nasal mucosa of infected mice at days 2 (N = 3) and 4 (N = 3) p.i. 151 
To that end, mice were euthanized by administration of a lethal dose of Avertin 152 
and exsanguinated. Virus titers in homogenized lungs and nasal mucosa were 153 
determined by immunofocus assay (FFU/ml) [30, 31, 35] using the anti-NA goat 154 
pAb A/Singapore/1/57 (CIV H3N2 LAIV) and the anti-HA A/equine/Miami/1/63 155 
mAb Equine 7.1 (CIV H3N8 LAIV). To assess immunogenicity and protection 156 
efficacy, mice (N = 12) were anesthetized and vaccinated i.n. with PBS or with a 157 
virus preparation containing 103 and 104 FFU of CIV H3N2 and H3N8 LAIV, 158 
respectively. In addition, a group of mice (N = 12) were inoculated 159 
intramuscularly (i.m) with a preparation containing 100 µl of a commercial CIV 160 
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H3N2 IIV (Zoetis) [31] and 100 µl of a commercial CIV H3N8 IIV (Novartis) [30]. 161 
Fifteen days after vaccination, mice were challenged i.n. with 105 FFU of WT 162 
H3N2 (N = 6) or H3N8 (N = 6) CIVs. After challenge, H3N2 or H3N8 WT viral 163 
replication in mice lungs was evaluated at days 2 (N=3) and 4 (N=3) p.i. 164 
Analysis of humoral responses 165 
Mouse sera were collected by submandibular bleeding 24 h prior to viral 166 
challenges to evaluate immune responses. The level of virus-specific antibodies 167 
present in the sera of vaccinated mice were evaluated by enzyme-linked 168 
immunosorbent assay (ELISA) using 96-well plates coated with lysates from 169 
mock-, H3N2 WT CIV- or H3N8 WT CIV-infected MDCK cells, as previously 170 
described [30, 31]. Presence of neutralizing antibodies was analyzed by Virus 171 
Neutralization (VN) assays where 100 FFU of H3N2 or H3N8 WT CIVs were 172 
incubated with two-fold serial dilutions (starting dilution 1:25) of heat inactivated 173 
sera as previously described [31]. 174 
 175 
RESULTS 176 
CIV H3N2 and H3N8 LAIVs co-infect cells in vitro 177 
In order to generate a bivalent LAIV that protects against both CIV subtypes, 178 
we blended our previously described individual CIV H3N8 and H3N2 LAIVs (Fig. 179 
1) [30, 31]. To analyze the identity of both LAIVs and to demonstrate that both 180 
viruses are able to co-infect cells in vitro, we infected MDCK cells with CIV H3N8 181 
and H3N2 LAIVs either individually or together and performed an 182 
immunofluorescence assay using antibodies that differentiate between the HA 183 
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and the NA proteins of H3N8 and H3N2 CIVs [31], respectively (Fig. 2). H3N8 184 
LAIV-infected cells were recognized by the anti-HA A/equine/Miami/1/63 H3N8 185 
mAb when cells were infected with H3N8 LAIV alone or mixed with the H3N2 186 
LAIV (Fig. 2, red fluorescence in the first and third columns). On the other hand, 187 
H3N2 LAIV-infected cells were recognized by the anti-NA pAb A/Singapore/1/57 188 
H3N2 when they were infected alone or in combination with H3N8 LAIV (Fig. 2, 189 
green fluorescence in the second and third columns). However, H3N2- or H3N8-190 
infected cells were not recognized with the anti-HA A/equine/Miami/1/63 H3N8 191 
mAb or the anti-NA pAb A/Singapore/1/57 H3N2, respectively. All infected cells, 192 
independently of the virus, were recognized by the anti-NP mAb HB-65 (Fig. 2, 193 
last column) included as internal control of infection. These results demonstrate 194 
the identity of both H3N8 and H3N2 LAIVs [31] and their ability to co-infect 195 
MDCK cells in vitro. 196 
The bivalent CIV LAIV is attenuated in vivo 197 
Since H3N8 and H3N2 LAIVs were attenuated in a mouse model of infection 198 
when compared with their respective CIVs WT [30, 31], we analyzed the 199 
replication of both LAIVs in the lower (lungs) and upper (nasal mucosa) 200 
respiratory tract of mice when they were administered together (Fig. 3). Two 201 
groups of mice were inoculated i.n. with viral preparations containing a constant 202 
amount of 103 FFU of H3N2 LAIV, and two different amounts (104 or 105 FFU) of 203 
H3N8 LAIV. We used these combinations based on the ability of H3N2 LAIV to 204 
replicate in vitro and in vivo more efficiently than H3N8 LAIV [30, 31]. In the lungs 205 
of mice vaccinated with 103 FFU of H3N2 LAIV and 104 FFU of H3N8 LAIV (Fig. 206 
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3A), we were not able to detect either LAIV at days 2 or 4 p.i. On the other hand, 207 
in the nasal mucosa (Fig. 3B), we were able to observe similar viral titers of 208 
~103-104 FFU/ml for both H3N8 and H3N2 LAIVs at days 2 and 4 p.i. Similarly, 209 
we could not detect either LAIV in the lungs of mice immunized with 103 FFU of 210 
H3N2 LAIV and 105 FFU of H3N8 LAIV at any day p.i. (Fig. 3C). However, in the 211 
nasal mucosa (Fig. 3D), H3N8 LAIV reached similar viral titers at both times p.i., 212 
while the viral titers of H3N2 LAIV were ~1 log lower at day 2 p.i. in relation to 213 
those obtained by H3N8 LAIV, or were not detected at day 4 p.i. These results 214 
suggest that replication of H3N8 LAIV impeded the efficient replication of H3N2 215 
LAIV and that our blended CIV LAIV is safe since we were not able to detect any 216 
of the LAIVs in the lungs of infected mice (Figs. 3A and 3C). Also, these results 217 
indicate that a dose of 103 FFU of H3N2 LAIV and 104 FFU of H3N8 allows 218 
similar level of replication of both viruses in the nasal mucosa of this mouse 219 
strain, which is important for efficient induction of protective immune responses 220 
(Figs. 3B and 3D). Notably, these results are comparable to those obtained 221 
previously using individual H3N8 [30] or H3N2 [31] LAIVs. 222 
The bivalent CIV LAIV is immunogenic and induces protection against 223 
challenge with H3N2 and H3N8 CIVs 224 
To evaluate the humoral responses and protection efficacy induced when both 225 
LAIVs were blended, we vaccinated mice i.n. with a virus preparation containing 103 226 
and 104 FFU of H3N2 and H3N8 LAIV, respectively; or mock-vaccinated with PBS (Figs. 227 
4 and 5). Additionally, and in order to compare our bivalent LAIV approach with the 228 
commercial available blended IIV, a group of mice was vaccinated i.m. with 100l of a 229 
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H3N2 IIV and 100l of a H3N8 IIV. Mice were then subdivided in two groups for 230 
subsequent challenges with H3N2 (Fig. 4) or H3N8 (Fig. 5) WT CIVs. Humoral immune 231 
responses were evaluated by ELISA using cell extracts from H3N2-infected MDCK cells 232 
(Figs. 4B and 5C) or H3N8-infected MDCK cells (Figs. 4C and 5B) [30, 31]. Antibodies 233 
against total H3N2 (Figs. 4B and 5C) or H3N8 (Figs. 4C and 5B) CIV proteins were 234 
detected in the sera from all LAIV or IIV vaccinated mice. Notably, humoral responses 235 
elicited by the bivalent LAIV against both CIVs were greater than in mice vaccinated 236 
with the bivalent IIV against either H3N2 (Figs. 4B and 5C) or H3N8 (Figs. 4C and 5B) 237 
CIVs. Neutralizing antibody responses, as determined by VN assay, against H3N2 (Fig. 238 
4D) and H3N8 (Fig. 5D) CIVs were similar in both LAIV- and IIV-vaccinated mice. 239 
To evaluate the protection efficacy of the bivalent LAIV against H3N2 or H3N8 WT 240 
CIV challenges, vaccinated mice were challenged with 105 FFU of H3N2 WT (Fig. 4E) 241 
or H3N8 WT (Fig. 5E) CIVs. In mock-vaccinated mice, we observed H3N2 WT viral 242 
titers of ~ 1 x 106 FFU/ml at days 2 and 4 post-challenge. On the other hand, in mice 243 
vaccinated with the bivalent LAIV, H3N2 WT was only detected in one mouse at day 2 244 
post-challenge and it was not detected at day 4 p.i. All mice vaccinated with the bivalent 245 
IIV showed H3N2 WT titers at day 2 post-challenge, although virus was not detected in 246 
any of the vaccinated mice at day 4 p.i. (Fig. 4E). Mock-vaccinated mice challenged 247 
with H3N8 WT (Fig. 5E), exhibited viral titers of ~ 106 and ~ 105 FFU/ml at days 2 and 4 248 
post-challenge, respectively; while mice vaccinated with the bivalent LAIV showed viral 249 
titers that were reduced ~ 4 logs (two mice) or not detected (one mouse) at day 2 post-250 
challenge. Notably, H3N8 WT virus was not detected at day 4 p.i. in mice vaccinated 251 
with the bivalent LAIV. All mice vaccinated with the bivalent IIV had detectable H3N8 252 
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WT viral titers (~ 104 FFU/ml) at day 2 p.i. and were not protected as those vaccinated 253 
with the bivalent LAIV (Fig. 5E).  254 
 255 
DISCUSSION 256 
Here we combined our previously described CIV H3N8 and H3N2 monovalent LAIVs 257 
[30, 31] (Fig. 1) to generate a bivalent CIV LAIV that confers protection against both 258 
subtypes of CIVs. Both CIV LAIVs were able to co-infect cells in vitro (Fig. 2). Moreover, 259 
in mice immunized with 103 of H3N2 and 104 FFU of H3N8 LAIVs both CIV LAIVs 260 
replicated similarly in the nasal mucosa (Fig. 3). However, neither CIV LAIV replicated 261 
in the lungs of intra-nasally vaccinated mice (Fig. 3), further demonstrating our initial 262 
results on the safety profile of the CIV LAIVs [30, 31]. In order to directly compare the 263 
immunogenicity and protection efficacy induced by the CIV bivalent LAIV with those 264 
induced by the CIV H3N8 and H3N2 monovalent LAIVs [30, 31], we utilized the same 265 
vaccination/challenge regimes as those previously used with the monovalent vaccines 266 
[30, 31]. The bivalent CIV LAIV induced greater humoral responses and better 267 
protection against H3N8 and H3N2 CIVs than those observed with a bivalent CIV IIV 268 
(Figs. 4 and 5) corroborating our previously results on the CIV LAIV superiority in terms 269 
of protection efficacy. 270 
Vaccination of dogs with CIV IIVs requires two i.m. injections separated a few weeks 271 
apart with 1ml of vaccine containing ~ 107 FFU equivalent of viral antigen. Taking into 272 
consideration that the average weight for a mouse (~ 20 g) is 500 times lower than the 273 
average weight of a beagle dog (~ 10 Kg), we used a 50 times higher (100 µl) dose of 274 
each CIV IIV in our mice experiments, the equivalent to ~ 106 FFU. Even under these 275 
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conditions the CIV bivalent LAIV containing only 103 and 104 FFU of H3N2 and H3N8 276 
LAIVs, respectively, conferred better protection than the one obtained with the bivalent 277 
CIV IIV in mice immunized with a single dose of each bivalent vaccine. Since the 278 
induction of neutralizing antibodies were only slightly higher in the case of CIV LAIVs 279 
versus IIVs, this better protection efficacy is probably linked to the ability of the CIV 280 
LAIVs to induce CD8 T-cell responses, which are not observed using the CIV IIVs [30, 281 
31]. 282 
Compared to the current blended IIV the bivalent LAIV approach provides the 283 
following advantages: it is administered i.n., therefore mimicking the natural route of 284 
influenza infection; requires significantly less virus to induce superior protection against 285 
WT CIV infections; stimulates more robust humoral response; elicits CD8 T-cell 286 
immunity which allows a more effective control of influenza infection with a single 287 
immunization; and as it is based on reverse genetics the system allows the generation 288 
of new LAIVs against other or newly introduced viruses. This blended CIV LAIV 289 
therefore likely represents an excellent option for the prevention and control of CIV 290 
infections if the results are translated to dogs. 291 
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FIGURE LEGENDS 306 
Figure 1. Schematic representation of a CIV H3N8 and H3N2 blended LAIV: 307 
We have previously developed and characterized monovalent CIV H3N8 (black) 308 
and H3N2 (red) LAIVs (top left). Both monovalent CIV LAIVs protected against 309 
homologous challenge with WT CIVs but not against heterologous CIV 310 
challenges (top right). A bivalent CIV LAIV, made of H3N8 and H3N2 LAIVs, 311 
(bottom left) was used to evaluate its ability to confer protection against H3N8 312 
and H3N2 CIV challenges (bottom right). 313 
Figure 2. Characterization of the bivalent CIV blended LAIV: MDCK cells 314 
were mock-infected or infected at high multiplicity of infection (MOI = 3) with the 315 
CIV H3N8 (black) or H3N2 (red) LAIVs, or co-infected with both LAIVs and 316 
incubated at 33ºC. At 12 h p.i., cells were fixed and stained with the indicated 317 
monoclonal or polyclonal antibodies against HA (H3N8 LAIV), NA (H3N2 LAIV) 318 
or NP (both H3N8 and H3N2 LAIVs). DAPI was also included for nuclear staining. 319 
Representative images are shown. Scale bars, 200 µM. 320 
Figure 3. Attenuation of the bivalent CIV H3N8 and H3N2 blended LAIV in 321 
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vivo: Female 6-to-8-week-old C57BL/6 mice (N = 6) were infected intranasally 322 
(i.n.) with the bivalent CIV LAIV using 103 FFU of H3N2 LAIV and 104 FFU of 323 
H3N8 LAIV (A-B), or 103 FFU of H3N2 LAIV and 105 FFU of H3N8 LAIV (C-D). 324 
Presence of CIV H3N8 and H3N2 LAIVs in the lungs (A and C) and the nasal 325 
mucosa (B and D) of infected mice were evaluated at days 2 (N = 3) and 4 (N = 326 
3) p.i. by immunofocus assay (FFU/ml) using a monoclonal antibody against 327 
A/equine/Miami/1/63 H3N8 HA (CIV H3N8 LAIV), or a polyclonal antibody 328 
against A/Singapore/1/57 H3N2 NA (CIV H3N2 LAIV) (Figure 1). Symbols 329 
represent data points for individual mice. ND, not detected. Bars, geometric 330 
mean viral titers. Dotted black lines indicates the limit of detection (200 FFU/ml).  331 
Figure 4. Immunogenicity and protection efficacy of the bivalent CIV LAIV 332 
against CIV H3N2: A) Schematic representation of the protocol used to assess 333 
humoral response and protection efficacy. Female 6- to-8-week-old C57BL/6 334 
mice (N = 6) were vaccinated with the bivalent CIV LAIV (103 FFU and 104 FFU 335 
of H3N2 and H3N8 LAIVs, respectively). Mice were also mock (PBS) vaccinated 336 
(N = 6) or vaccinated (N = 6) i.m. with a bivalent CIV IIV (100 l/mice of H3N2 IIV, 337 
Zoetis, and 100 l/mice of H3N8 IIV, Nobivac). B-C) Induction of humoral 338 
responses: 14 days post-vaccination, mice were bled and the sera were 339 
collected and evaluated individually by ELISA for IgG antibodies against total 340 
viral proteins using cell extracts of MDCK cells infected with H3N2 (B) or H3N8 341 
(C) WT CIVs. Mock-infected cell extracts were used to evaluate the specificity of 342 
the antibody response. OD, optical density. Data represent the means +/- SDs of 343 
the results for 6 individual mice. D) Virus neutralization (VN) titers against CIV 344 
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H3N2: sera from vaccinated mice were evaluated for the presence of neutralizing 345 
antibodies using 100 FFU of CIV H3N2 WT and 2-fold serial dilutions of the 346 
indicated pooled mice sera. Data represent the means +/- SDs. ND, not detected. 347 
E) Protection efficacy against CIV H3N2: 15 days post-vaccination, mice (N = 348 
6) were challenged with 105 FFU of CIV H3N2 WT and viral titers at days 2 (N = 349 
3) and 4 (N = 3) p.i. from lung homogenates were evaluated by immunofocus 350 
assay (FFU/ml) using the anti-NP mAb HT-103. Symbols represent data points 351 
for individual mice. &, virus not detected in 2 mice; ND, not detected. Bars, 352 
geometric mean lung viral titers. Dotted black lines indicate the limit of detection 353 
(200 FFU/ml).  354 
Figure 5. Immunogenicity and protection efficacy of the bivalent CIV LAIV 355 
against CIV H3N8: A) Schematic representation of the protocol used to assess 356 
the humoral response and protection efficacy induced by the bivalent CIV LAIV 357 
against CIV H3N8. Female 6- to-8-week-old C57BL/6 mice (N = 6) were 358 
vaccinated with the bivalent CIV LAIV (103 FFU and 104 FFU of H3N2 and H3N8 359 
LAIVs, respectively), mock-vaccinated or vaccinated i.m. with a bivalent IIV (as 360 
previously indicated in Figure 4). B-C) Induction of humoral responses: 14 361 
days post-vaccination, mice were bled and the sera were collected and evaluated 362 
individually by ELISA for IgG antibodies against total viral proteins using cell 363 
extracts of MDCK cells infected with H3N8 (B) or H3N2 (C) WT CIVs. D) Virus 364 
neutralization (VN) titers against CIV H3N8: mice sera were also assessed for 365 
the presence of neutralizing antibodies using 100 FFU of CIV H3N8 WT and 2-366 
fold serial dilutions of the indicated sera. Data represent the means +/- SDs. ND, 367 
 17 
not detected. E) Protection efficacy against CIV H3N8: 15 days post-368 
vaccination, mice (N = 6) were challenged with 105 FFU of CIV H3N8 WT and 369 
viral titers from lung homogenates were evaluated by immunofocus assay 370 
(FFU/ml) at days 2 (N = 3) and 4 (N = 3) post-challenge, using the anti-NP mAb 371 
HT-103. Symbols represent data for individual mice. *, virus not detected in 1 372 
mouse; &, virus not detected in 2 mice; ND, not detected. Bars, geometric mean 373 
lung viral titers. Dotted black lines indicate the limit of detection (200 FFU/ml). 374 
 375 
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